Vanda Pharmaceuticals Inc.
Close on Oct 19, 2026
- Market cap
- $246.33M
- P/E (TTM)
- –
- Dividend yield
- –
About Vanda Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Vanda Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes therapies for central nervous system disorders and other medical conditions. Its commercial product lineup includes Fanapt for schizophrenia and bipolar I disorder, Hetlioz for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome sleep disturbances, Ponvory for relapsing forms of multiple sclerosis, and Nereus for motion-induced vomiting. The company operates in a product segment and distributes its medications primarily to wholesale drug distributors and specialty pharmacies.
The company is based in Washington, D.C., where it maintains its principal executive offices. Its commercial operations center on the United States, alongside product distribution in select international markets including Canada, Israel, and European nations such as the United Kingdom. Its operations encompass four commercial-stage prescription medicines along with multiple drug candidates undergoing clinical development.
Summary of the business section of Vanda Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Vanda Pharmaceuticals Inc.
- Founded
- 2002
- Headquarters
- Washington, DC
- Address
- 2200 Pennsylvania Ave Nw, Suite 300e 20037
- Phone
- (202) 734-3400
- Website
- www.vandapharma.com
- Employees
- 533, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Washington, District of Columbia
Stock & identifiers
- Ticker
- VNDA
- Exchange
- Nasdaq
- IPO date
- Apr 13, 2006
- Shares outstanding
- 60M, Jul 30, 2026
- Public float
- $268.70M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1347178
- CUSIP
- 921659108
- ISIN
- US9216591084
- LEI
- 529900AY8VOOQBKJ0O70
- EIN
- 03-0491827
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mihael Hristos Polymeropoulos | President and CEO, Director | 2,704,496 |
| Daniel Patrick McGuire | SVP, GC and Secretary | 109,982 |
| Scott Laverne Howell | VP and Chief People Officer | 109,620 |
| Christos Vasilios Mihael Polymeropoulos | Senior VP, Medical Director | 129,791 |
| Joakim Wijkstrom | SVP, Chief Marketing Officer | 333,469 |
| Timothy Williams | SVP & General Counsel | 377,450 |
| Kevin Patrick Moran | SVP, CFO & Treasurer | 412,015 |
| Gunther Birznieks | SVP, Business Development | 494,197 |
| Richard W. Dugan | Director | 219,054 |
| Phaedra Chrousos | Director | 164,950 |
| Anne Sempowski Ward | Director | 160,667 |
| Stephen Ray Mitchell | Director | 112,846 |
| Tage Honore | Director | 135,069 |
| Charles Cliff Duncan | Director | 98,701 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Mihael H. Polymeropoulos | $3.85M | $7.63M | $1.44M | $67 | $120 |
| FY2024 Dr. Mihael H. Polymeropoulos | $3.90M | $4.34M | $1.35M | $36 | $91 |
| FY2023 Dr. Mihael H. Polymeropoulos | $3.72M | $1.78M | $1.36M | $32 | $92 |
| FY2022 Dr. Mihael H. Polymeropoulos | $4.27M | $859.61K | $1.51M | $56 | $89 |
| FY2021 Dr. Mihael H. Polymeropoulos | $6.19M | $5.60M | $1.96M | $119 | $99 |
| FY2020 Dr. Mihael H. Polymeropoulos | $2.91M | $2.06M | $1.15M | $80 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“We had 533 full-time employees as of December 31, 2025, compared with 368 employees as of December 31, 2024.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 17, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
| Dec 7, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 25, 2008 | Listing | Registration of securities on an exchange (Form 8-A) |
| Apr 13, 2006 | IPO | Initial public offering priced (424B4 prospectus) |